

LIST OF FIGURES

| Figure No. | Figure Caption | Pg. No. |
|-------------------|---|----------------|
| Fig. 2-1 | Structure of Human Uterus | 15 |
| Fig. 2-2 | Histology of Human Uterus | 17 |
| Fig. 2-3 | Vascular Supply to the Uterus | 18 |
| Fig. 2-4 | Representation of First Uterine Pass Effect | 21 |
| Fig. 2-5 | Chemical Structure of PTX | 26 |
| Fig. 2-6 | Mechanism of Action of PTX | 28 |
| Fig. 2-7 | Chemical structure of CBP | 31 |
| Fig. 2-8 | Mechanism of action of CBP | 32 |
| Fig. 2-9 | Vaginal Histology | 37 |
| Fig. 2-10 | Intra Vaginal Rings (Matrix type) | 38 |
| Fig. 2-11 | Intra Vaginal Rings (Reservoir type) | 39 |
| Fig. 2-12 | Mechanism of ultradeformability for penetration | 40 |
| Fig. 3-1 | Overlay chromatogram for PTX | 57 |
| Fig. 3-2 | Calibration Plot for PTX (n=3) | 58 |
| Fig. 3-3 | Overlay chromatogram for CBP | 62 |
| Fig. 3-4 | Calibration Plot for CBP (n=3) | 63 |
| Fig. 4-1 | FTIR spectrum of PTX | 70 |
| Fig. 4-2 | FTIR spectrum of CBP | 70 |
| Fig. 4-3 | DSC thermograms of A) pure PTX and B) PTX-excipients mixture | 71 |
| Fig. 4-4 | DSC thermograms of A) pure CBP and B) CBP-excipients mixture | 72 |
| Fig. 4-5 | Appearance of dispersion before and after sonication | 73 |
| Fig. 4-6 | Pre-sonicated blank vesicular dispersion under microscope | 73 |
| Fig. 4-7 | Solution A - Needle shaped crystals of PTX at initiation | 77 |
| Fig. 4-8 | Solution B - Intermediate homogeneous growth of PTX crystals | 77 |
| Fig. 4-9 | Solution C - spherulite formation/heterogenous crystallization of PTX | 78 |
| Fig. 4-10 | Solution D - Di-/Trihydrate axialite formation of PTX | 78 |
| Fig. 5-1 | Pareto and Normal plots for %EE | 98 |
| Fig. 5-2 | Pareto and Normal plots for DI | 99 |
| Fig. 5-3 | Pareto and Normal plots for Vesicle Size | 100 |
| Fig. 5-4 | Contour Plot and response surface plots for %EE | 107 |
| Fig. 5-5 | Contour Plot and response surface plots for DI | 108 |
| Fig. 5-6 | Desirability Plot and Overlay plot for the model | 108 |
| Fig. 6-1 | Pareto and Normal plots for %EE | 124 |
| Fig. 6-2 | Pareto and Normal plots for DI | 125 |
| Fig. 6-3 | Pareto and Normal plots for Vesicle Size | 126 |

| | | |
|-----------|--|-----|
| Fig. 6-4 | Contour Plot and response surface plots for %EE | 133 |
| Fig. 6-5 | Contour Plot and response surface plots for DI | 134 |
| Fig. 6-6 | Desirability Plot and Overlay plot with design space for the model | 135 |
| Fig. 7-1 | PTX-UDNVs vesicle size analysis | 144 |
| Fig. 7-2 | PTX-UDNVs surface charge (zeta potential) analysis | 144 |
| Fig. 7-3 | Transmission electron microscopic image of optimized PTX-UDNVs | 146 |
| Fig. 7-4 | In Vitro drug release of PTX-UDNVs and Plain Drug Suspension | 148 |
| Fig. 7-5 | In Vitro drug release profile of PTX-UDNVs from IVR | 149 |
| Fig. 7-6 | CBP-UDNVs vesicle size analysis | 155 |
| Fig. 7-7 | CBP-UDNVs surface charge (zeta potential) analysis | 155 |
| Fig. 7-8 | Transmission electron microscopic image of optimized CBP-UDNVs | 157 |
| Fig. 7-9 | In Vitro drug release of CBP-UDNVs and Plain Drug Solution | 159 |
| Fig. 7-10 | In Vitro drug release profile of CBP-UDNVs from IVR | 160 |
| Fig. 8-1 | Vaginal tissue treated with Phosphate Buffer pH 4.5 (Negative Control) for A) One week B) Two weeks | 172 |
| Fig. 8-2 | Vaginal tissue treated with Isopropyl Alcohol (Positive Control) for A) One week B) Two weeks | 172 |
| Fig. 8-3 | Vaginal tissue treated with PTX-UDNVs formulation for A) One week B) Two weeks | 173 |
| Fig. 8-4 | Vaginal tissue treated with CBP-UDNVs formulation for A) One week B) Two weeks | 173 |
| Fig. 8-5 | Vaginal tissue treated with PTX-plain drug suspension for A) One week B) Two weeks | 174 |
| Fig. 8-6 | Vaginal tissue treated with CBP-plain drug solution for A) One week B) Two weeks | 174 |
| Fig. 8-7 | Qualitative examination of haemolysis of RBC when incubated with A) Normal Saline (Negative Control) B) Distilled water (Positive control) C) Marketed formulation of PTX D) PTX-UDNVs formulation | 175 |
| Fig. 8-8 | Quantitative measurement of %Haemolysis of RBC when incubated with PTX-UDNVs formulation and PTX-Marketed formulation | 176 |
| Fig. 8-9 | Qualitative examination of haemolysis of RBC when incubated with A) Normal Saline (Negative Control) B) Distilled water (Positive control) C) Marketed formulation of CBP D) CBP-UDNVs formulation | 176 |
| Fig. 8-10 | Quantitative measurement of %Haemolysis of RBC when incubated with CBP-UDNVs formulation and CBP-Marketed formulation | 177 |

| | | |
|------------|--|-----|
| Fig. 9-1 | Cytotoxicity of PTX marketed formulation and PTX-UDNVs | 185 |
| Fig. 9-2 | IC50 values of PTX-marketed formulation and PTX-UDNVs | 186 |
| Fig. 9-3 | Cytotoxicity of CBP marketed formulation and CBP-UDNVs | 187 |
| Fig. 9-4 | IC50 values of CBP-marketed formulation and CBP-UDNVs | 188 |
| Fig. 9-5 | Quantitative intracellular uptake histograms for A) FITC dye solution treated sample B) FITC loaded PTX-UDNVs treated sample C) FITC loaded CBP-UDNVs treated sample | 190 |
| Fig. 9-6 | Mean fluorescence intensity plot of plain dye solution, FITC-PTX-UDNVs and FITC-CBP-UDNVs | 191 |
| Fig. 10-1 | Mean radiochemical purity for radiolabelled PTX (n=3) | 203 |
| Fig. 10-2 | In vitro stability of radiolabelled PTX (^{99m} Tc-PTX) | 204 |
| Fig. 10-3 | DTPA transchelation study for ^{99m} Tc-PTX complex | 205 |
| Fig. 10-4 | Uterine targeting efficiency of PTX-UDNVs and Plain drug | 208 |
| Fig. 10-5 | Gamma scintigraphic images obtained at A) 0.25 h B) 1 h C) 2 h D) 24 h E) 48 h after ^{99m} Tc-PTX-UDNVs administration via vaginal route | 208 |
| Fig. 10-6 | Gamma scintigraphic images obtained at A) 0.25 h B) 1 h C) 2 h D) 24 h E) 48 h after ^{99m} Tc-PTX plain drug administration via vaginal route | 209 |
| Fig. 10-7 | Quantitative systemic absorption study of ^{99m} Tc-PTX loaded UDNVs and plain drug | 210 |
| Fig. 10-8 | Ultrasonography images of rabbit uterine horns showing clear lumen - Negative control | 212 |
| Fig. 10-9 | Ultrasonography images of rabbit uterine horns showing lumen with Endometrial Carcinoma - Positive control | 213 |
| Fig. 10-10 | Ultrasonography images of rabbits treated with PTX-UDNVs formulation A) after 2 weeks B) after 4 weeks | 214 |
| Fig. 10-11 | Ultrasonography images of rabbits treated with CBP-UDNVs formulation A) after 2 weeks B) after 4 weeks | 215 |